RNK08954 clinical trials
Also written RNK08954.
How each study uses RNK08954 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the RNK08954 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RNK08954
- 3
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 2 |
Who runs them
Industry 4 · Other 0
Ranok Therapeutics (Hangzhou) Co., Ltd. (2) · Ranok Therapuetics Co. Ltd. (1) · InxMed (Shanghai) Co., Ltd. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test RNK08954.
- Nov 2026To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.Phase 2 · Ranok Therapeutics (Hangzhou) Co., Ltd.
- Dec 2026A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male SubjectsPhase 1 · Ranok Therapeutics (Hangzhou) Co., Ltd.
Studies
Open first, then newest update. How each study uses RNK08954 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2InxMed (Shanghai) Co., Ltd.NCT07441174Written as IN10018 in combination with RNK08954
- To Evaluate the Safety and Efficacy of RNK08954 in Patients With Advanced Gynecological Tumors.Not yet recruitingPhase 2Ranok Therapuetics Co. Ltd.NCT07848893Written as RNK08954
- A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male SubjectsNot yet recruitingPhase 1Ranok Therapeutics (Hangzhou) Co., Ltd.NCT07334262Written as RNK08954
- To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.RecruitingPhase 2Ranok Therapeutics (Hangzhou) Co., Ltd.NCT07303465Written as RNK08954